Clot Busting Drugs - Worldwide

The global clot busting drugs market size accounted for USD 33,340 million in 2024 and is expected to exceed around USD 68,070 million by 2034, growing at a CAGR of 7.4% from 2024 to 2034. 

The clot-busting drugs market has grown due to the increasing number of deaths due to stroke, which has led to the expansion of the thrombolytic drug market worldwide. Stroke is the second leading cause of death worldwide, causing approximately 5.5 million deaths each year. In addition to the severe pain caused by stroke, which causes long-term disability in up to 50% of survivors, the mortality rate is also high.

• For Instance, Roche’s commitment to integrating therapeutics into medicine fits well with the existing model, making the company a leader in addressing the important health issues surrounding blood clotting.

The demand in the clot-busting drugs market continues to increase as global opportunities include resources for developing innovative drugs that address unmet medical needs, such as more effective, safer thrombolytics, and have fewer side effects, as demand for thrombolytics continues to grow. Collaboration between pharmaceutical companies and research centers can lead to competition in drug combinations or new therapies, attract investment, and increase competition. Expansion into developed regions is also expected to increase as hospitalization and advanced care services continue to grow.